BioInvent is focused on developing novel immuno-modulatory antibodies for cancer therapy. BioInvent’s innovative antibodies may significantly improve the efficacy of currently available immuno-modulatory checkpoint inhibitor therapies and/or activate anti-cancer immunity in currently non-responding patients and cancer types.

Our publications

BioInvent's cutting-edge research is acknowledged through high quality scientific publications. The company's scientists have a documented track-record of being accepted for publication in high impact-factor publications.